Therapeutic drug monitoring of clozapine and relapse – a retrospective study of routine clinical data

2003 ◽  
Vol 41 (01) ◽  
pp. 3-13 ◽  
Author(s):  
S. Ulrich ◽  
B. Baumann ◽  
R. Wolf ◽  
D. Lehmann ◽  
B. Peters ◽  
...  
2013 ◽  
Vol 35 (8) ◽  
pp. e79 ◽  
Author(s):  
K.R. Ing Lorenzini ◽  
C. Samer ◽  
J. Pugin ◽  
S. Harbarth ◽  
P. Bonnabry ◽  
...  

1992 ◽  
Vol 26 (5) ◽  
pp. 675-678 ◽  
Author(s):  
John L. Foy ◽  
Richard C. Eastman ◽  
Reggie C. Nealon ◽  
Patty M. Bowen ◽  
Mary L. Pengelly ◽  
...  

OBJECTIVE: To develop and implement an automated therapeutic drug monitoring system for accessing data from endocrine clinic patients who had been prescribed insulin, oral hypoglycemic agents (OHA), or levothyroxine. DATA SOURCES: We designed a computer system to retrieve clinical data from the Medical Information System (MIS), a centralized hospital computer system, and import this information directly into a Macintosh personal computer. Physician entry of prescriptions for insulin, OHA, or levothyroxine into MIS formed the basis for a computer program to retrieve daily diagnostic and prescription information, demographics, and laboratory analyses, including blood glucose and glycosylated hemoglobin for insulin and OHA orders and free and total thyroxine, total triiodothyronine, and thyroid stimulating hormone for levothyroxine orders. The information was imported into a database program (4th Dimension). RESULTS: The system identifies laboratory values outside of predetermined therapeutic ranges, maintains an up-to-date patient profile, and edits and generates reports. Preliminary experience suggests that automation eliminates 75–90 percent of the time required to manually collect the same information, and improves the accuracy, comprehensiveness, and utility of reports. CONCLUSIONS: Automated therapeutic drug monitoring minimizes the time required to collect clinical data, alerts clinicians to potential problems, and provides a means to assess overall therapeutic management. Our methodology can be used to evaluate other medications in a variety of general or specialty clinics.


2021 ◽  
pp. bjophthalmol-2021-319072
Author(s):  
Lucas Sejournet ◽  
Sebastien Kerever ◽  
Thibaud Mathis ◽  
Laurent Kodjikian ◽  
Yvan Jamilloux ◽  
...  

AimTo assess the relevance of therapeutic drug monitoring (TDM) of adalimumab (ADA) treatment for the control of intraocular inflammation and treatment adjustment in chronic non-infectious uveitis (CNIU).MethodsRetrospective study of CNIU patients treated with ADA and for whom at least one dosage of serum ADA level and an antibodies against ADA (AAA) serology were performed, between June 2003 and July 2019.ResultsA total of 44 ADA-treated patients benefited from a TDM. A total of 48/79 (61%) TDM were performed in responders, 11/79 (14%) in primary non-responders, and 20/79 (25%) in secondary non-responders. Responders had significantly higher ADA levels than non-responders (p=0.0004). AAA were detectable in six patients, they were primary non-responders (n=2), secondary non-responders (n=3) or responders (n=1). In the five non-responders and immunised patients, ADA was switched (to golimumab or methotrexate). Among non-responders, TDM led to an increased frequency of injections 12/31 (38%), increased dose 1/31 (3%) and switch of treatment 10/31 (32%) (one missing data). No modification of biotherapy was performed 7/31 (22%) and only local or oral corticotherapy was adjusted. In 24/31 cases of therapeutic adjustment in non-responders, an improvement was observed in 87% of cases. Among responders for whom the ADA level was above the efficacy threshold, the frequency of injections was decreased for 15/31 (48.4%) cases and no relapse was observed in 12/15 (80%) cases.ConclusionTDM of ADA treatment proved relevant to provide CNIU patients with a personalised and optimised treatment course (in terms of frequency and type of drug).


2020 ◽  
Vol Volume 13 ◽  
pp. 4105-4113
Author(s):  
Dan Sun ◽  
Tao Zhang ◽  
Jie Mi ◽  
Yuzhu Dong ◽  
Yang Liu ◽  
...  

Author(s):  
Whitley M. Yi ◽  
Kelly E. Schoeppler ◽  
Jaclyn Jaeger ◽  
Scott W. Mueller ◽  
Robert MacLaren ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document